[Value of malarone in therapy of malaria tropica]. / Stellenwert von Malarone in der Therapie der Malaria tropica.
Med Klin (Munich)
; 97(8): 455-8, 2002 Aug 15.
Article
em De
| MEDLINE
| ID: mdl-12229244
ABSTRACT
BACKGROUND:
A widespread resistance of falciparum malaria to common antimalaria drugs is observed during the last years. Long-distance travel to high-risk destinations of falciparum malaria will contribute to increased exposition of travelers to highly resistant parasites. PHARMACOLOGY Malarone (GlaxoSmithKline) is a fixed combination of atovaquone and proguanil licensed for prophylaxis and treatment of falciparum malaria. Both atovaquone and proguanil demonstrate synergistic activity against liver and blood schizonts. Malarone is well tolerated with a low rate of side effects. Malarone has an excellent efficacy profile in nonimmune subjects.CONCLUSIONS:
Malarone appears to be a valuable alternative malaria prophylaxis in case of intolerance of other antimalaria drugs. Atovaquone/proguanil is effective in treating acute uncomplicated malaria caused by multiresistant strains of Plasmodium falciparum.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proguanil
/
Naftoquinonas
/
Malária Falciparum
/
Antimaláricos
Tipo de estudo:
Clinical_trials
Limite:
Animals
/
Humans
Idioma:
De
Revista:
Med Klin (Munich)
Ano de publicação:
2002
Tipo de documento:
Article